Items Tagged ‘PD1 Inhibitor’

March 8, 2019

FDA Approves Lonsurf® for Treatment of Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

By

The United States Food and Drug Administration (FDA) has approved Lonsurf® (trifluridine/tipiracil)) as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. About Lonsurf Lonsurf consists of […]

View full entry

Tags: checkpoint inhibitor, Gastric Cancer, immunotherapy, keytruda, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine


January 17, 2018

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

By

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC. Interim results […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine